Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Cefdinir
Overview
What is Cefdinir?
What does Cefdinir look like?



What are the available doses of Cefdinir?
Sorry No records found.
What should I talk to my health care provider before I take Cefdinir?
Sorry No records found
How should I use Cefdinir?
INDICATIONS AND USAGE
What interacts with Cefdinir?
Sorry No Records found
What are the warnings of Cefdinir?
Sorry No Records found
What are the precautions of Cefdinir?
General
Array
DOSAGE AND ADMINISTRATION
Information for Patients
Drug Interactions
Drug/Laboratory Test Interactions
Carcinogenesis, Mutagenesis, Impairment of Fertility
in vitro
in vivo
Pregnancy
Labor and Delivery
Nursing Mothers
Pediatric Use
Geriatric Use
Array
DOSAGE AND ADMINISTRATION
What are the side effects of Cefdinir?
Clinical Trials – Cefdinir Capsules (Adult and Adolescent Patients)
a | ||
Incidence ≥1% | Diarrhea | 15% |
Vaginal moniliasis | 4% of Women | |
Nausea | 3% | |
Headache | 2% | |
Abdominal pain | 1% | |
Vaginitis | 1% of Women | |
Incidence <1% but >0.1% | Rash | 0.9% |
Dyspepsia | 0.7% | |
Flatulence | 0.7% | |
Vomiting | 0.7% | |
Abnormal stools | 0.3% | |
Anorexia | 0.3% | |
Constipation | 0.3% | |
Dizziness | 0.3% | |
Dry mouth | 0.3% | |
Asthenia | 0.2% | |
Insomnia | 0.2% | |
Leukorrhea | 0.2% of Women | |
Moniliasis | 0.2% | |
Pruritus | 0.2% | |
Somnolence | 0.2% | |
a | ||
Incidence ≥1% | ↑Urine leukocytes | 2% |
↑Urine protein | 2% | |
↑Gamma-glutamyltransferase | 1% | |
↓Lymphocytes, ↑Lymphocytes | 1%, 0.2% | |
↑Microhematuria | 1% | |
Incidence <1% but >0.1% | ↑Glucose | 0.9% |
↑Urine glucose | 0.9% | |
↑White blood cells, ↓White blood cells | 0.9%, 0.7% | |
↑Alanine aminotransferase (ALT) | 0.7% | |
↑Eosinophils | 0.7% | |
↑Urine specific gravity, ↓Urine specific gravity | 0.6%, 0.2% | |
↓Bicarbonate | 0.6% | |
↑Phosphorus, ↓Phosphorus | 0.6%, 0.3% | |
↑Aspartate aminotransferase (AST) | 0.4% | |
↑Alkaline phosphatase | 0.3% | |
↑Blood urea nitrogen (BUN) | 0.3% | |
↓Hemoglobin | 0.3% | |
↑Polymorphonuclear neutrophils (PMNs), ↓PMNs | 0.3%, 0.2% | |
↑Bilirubin | 0.2% | |
↑Lactate dehydrogenase | 0.2% | |
↑Platelets | 0.2% | |
↑Potassium | 0.2% | |
↑Urine pH | 0.2% |
Clinical Trials - Cefdinir for Oral Suspension (Pediatric Patients)
Array | ||
Incidence ≥ 1% | Diarrhea | 8% |
Rash | 3% | |
Vomiting | 1% | |
Incidence <1% but >0.1% | Cutaneous moniliasis | 0.9% |
Abdominal pain | 0.8% | |
Leukopenia | 0.3% | |
Vaginal moniliasis | 0.3% of girls | |
Vaginitis | 0.3% of girls | |
Abnormal stools | 0.2% | |
Dyspepsia | 0.2% | |
Hyperkinesia | 0.2% | |
Increased AST | 0.2% | |
Maculopapular rash | 0.2% | |
Nausea | 0.2% | |
a | ||
Incidence ≥1% | ↑Lymphocytes, ↓Lymphocytes | 2%, 0.8% |
↑Alkaline phosphatase | 1% | |
↓Bicarbonate | 1% | |
↑Eosinophils | 1% | |
↑Lactate dehydrogenase | 1% | |
↑Platelets | 1% | |
↑PMNs, ↓PMNs | 1%, 1% | |
↑Urine protein | 1% | |
Incidence <1% but >0.1% | ↑Phosphorus, ↓Phosphorus | 0.9%, 0.4% |
↑Urine pH | 0.8% | |
↓White blood cells, ↑White blood cells | 0.7%, 0.3% | |
↓Calcium | 0.5% | |
↓Hemoglobin | 0.5% | |
↑Urine leukocytes | 0.5% | |
↑Monocytes | 0.4% | |
↑AST | 0.3% | |
↑Potassium | 0.3% | |
↑Urine specific gravity, ↓Urine specific gravity | 0.3%, 0.1% | |
↓Hematocrit | 0.2% |
Postmarketing Experience
Cephalosporin Class Adverse Events
Array
Array
Array
What should I look out for while using Cefdinir?
Sorry No records found
What might happen if I take too much Cefdinir?
How should I store and handle Cefdinir?
Store between 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F).Do not refrigerate. Keep the bottle in the outer carton when not in use.The product should be used within three months after it has been opened.Store between 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F).Do not refrigerate. Keep the bottle in the outer carton when not in use.The product should be used within three months after it has been opened.Store between 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F).Do not refrigerate. Keep the bottle in the outer carton when not in use.The product should be used within three months after it has been opened.Enter section text here
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Non-Clinical Toxicology
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).